News Hub | News Direct

Gamelancer Media beats its own forecasts with 2Q financial results

Gamelancer Media Corp

Gamelancer Media Corp CEO Jon Dwyer joined Steve Darling from Proactive to announce the company's financial achievements for the second quarter of 2023. The reported results surpassed management's expectations, showcasing an impressive 171% growth in revenue to C$1.42 million for the quarter ended June 30, 2023, compared to the same period in 2022. Dwyer emphasized to Proactive that the 2Q 2023 financial report not only highlights Gamelancer's exceptional revenue growth but also underscores the company's capacity to foster sustainable growth both in terms of revenue and network expansion. He emphasized that Gamelancer's unique value proposition, which combines owned and operated channels with its creative studio JoyBox, sets the stage for a distinctive media offering to brands. Dwyer also shared the company's ongoing efforts to optimize operational costs, a strategy that aligns with its goal of achieving positive underlying earnings (EBITDA) results by the fourth quarter of 2023. This commitment to financial efficiency and strategic growth positions Gamelancer for continued success in the competitive media landscape. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

August 17, 2023 12:44 PM Eastern Daylight Time

Video

Family Tech for School and Home

News Media Group, Inc.

Contact Details News Media Group, Inc. Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

August 17, 2023 12:01 PM Eastern Daylight Time

Video

Harvest Thermal Earns Inclusion in CEC Title 24 Compliance Software

Harvest Thermal

The electronic rulebook of Title 24 compliance for energy now includes Harvest Thermal’s smart thermal battery solution as an efficiency option. The California energy code for new construction and major remodels is becoming increasingly challenging to meet. Architects, homebuilders and remodelers need more cost-effective solutions to include in their projects. Harvest Thermal offers project developers a climate-friendly and cost-effective tool to meet code requirements. Its unique thermal battery solution uses a single heat pump for both heating and hot water. The smart Harvest Pod leverages cheap, clean electricity to store heat at midday while releasing it to the home whenever needed. Smart controls optimize for homeowner comfort while delivering up to 45% lower energy costs and 90% carbon reductions compared to gas. “Harvest Thermal’s inclusion in the CEC Title 24 database is very significant for architects, homebuilders and remodelers,” said Pierre Delforge, Head of Product and Operations at Harvest Thermal. “They will see outsized benefits with significantly lower EDR scores, lowering their costs and improving the performance of their buildings.” Building plans submitted for permitting must achieve scores at or below the Energy Design Rating (EDR) compliance threshold as calculated by the CBECC-Res compliance software. Plans that include Harvest Thermal get extra credit, lowering both Efficiency and Total EDR scores, and helping to avoid other more costly measures. Harvest Thermal also qualifies for the new California Electric Homes Program (CalEHP) for all-electric new construction, bringing more value to homebuilders’ projects. The technology fits into recognizable floorplans, enabling developers to seamlessly integrate Harvest into their designs. For more information on how to incorporate Harvest Thermal into the CBECC-Res database as a combined heat and hot water system see the instructions in this presentation. Harvest Thermal is redesigning home heating, cooling and hot water for the planet. Its market-leading thermal battery system cuts carbon emissions by 90% from home heating and hot water compared to gas and 50% compared to heat pumps without storage. The cloud-connected Harvest Pod leverages machine learning software, sensors, and controls to reduce carbon emissions and save on monthly heating bills. It also supports a cleaner, cheaper, and more resilient grid. Founded in 2019, Harvest Thermal has received support from the National Science Foundation, the California Energy Commission, Peninsula Clean Energy, and leading private investors. In 2023, Harvest Thermal was named to Fast Company’s Most Innovative Companies list; awarded NREL Industry Growth Forum’s People’s Choice Award; and won a Silver Edison Award for Sustainable Design in the category of Consumer Solutions. Contact Details Harvest Thermal David Tuft +1 202-494-0813 david@harvest-thermal.com Company Website https://www.harvest-thermal.com/

August 17, 2023 08:00 AM Pacific Daylight Time

Image

Portfolio Trading Insights on H1 2023: Volumes and Execution Quality Take Center Stage

Tradeweb

The first half of 2023 offered a volatile macro backdrop for U.S. credit markets, as elevated inflation, rates uncertainty and an ongoing banking crisis continued to weigh on our markets. Despite these hurdles, one constant theme in credit markets has been the use of portfolio trading to move large baskets of risk. Tradeweb has been the market leader in electronifying this protocol and our growth has continued through 2023, with combined U.S. Investment Grade (IG) and U.S. High Yield (HY) volumes in portfolio trading up 22% in the first half of 2023 compared with prior year period. This momentum continued into July; we estimate portfolio trading made up 6% [1] share of total TRACE in July 2023, which is the highest we’ve seen since November 2021. In this piece we highlight some of the trends we’ve seen in portfolio trading over the first six months of 2023 – and what this could mean for the next wave of portfolio trading innovation. For example, in response to growing client engagement and interest in using the protocol in different ways, we recently introduced ‘Bulk Crossing’ functionality within portfolio trading to allow clients and dealers to trade more efficiently by trading hundreds (or thousands) of corporate bonds with Treasury hedges, while consolidating the numerous Treasury trades into one ticket per benchmark. This feature allows both clients and dealers to trade more efficiently by reducing their number of tickets, and has grown in popularity for both Net Proceeds and Trade-at-Close (or Ref+) portfolio trades. Measuring the Size of the U.S. Portfolio Trading Market – An Update On May 15, 2023, the FINRA TRACE reporting rules took effect which require dealers to start reporting their portfolio trade transactions to TRACE. This change signifies how far portfolio trading has come over the past five years; it is a testament to the increased electronification of this protocol and of credit markets more broadly. The new requirements allow market participants to achieve a better understanding of the size of the market and therefore adjust their pricing models to consume these trades in a more informed way. This new reporting metric has also allowed us to validate our model for estimating portfolio trading market size on TRACE (discussed in more detail here ). We will continue to monitor the performance of our portfolio trading estimation model as more portfolio trades are tagged on TRACE over the coming months. [1] Based on TRACE Portfolio Trading Execution Volumes Vary Throughout the Month Portfolio trading is utilized by clients for a multitude of reasons. This can range from very specific sector level views to huge monthly or quarterly rebalances. Month-end tends to be a popular time for portfolio trades for a variety of reasons. Below we illustrate the average day’s volume given its position in the month during the first half of 2023 vs the first half of 2022. Looking at the chart below, the final week of the month averaged 42% more volume as compared to the previous weeks during the month. This trend helped drive the overall increase in portfolio trading over the last year. One reason that month-end is a popular time for portfolio trades is that the protocol provides an easy way for clients to rebalance their portfolio to maintain their monthly mandates and exposures. These types of rebalancing trades are typically slightly larger in size and have more line items than other portfolio trades. We can see this activity in the data: in H1 2023, portfolio trade baskets traded on Tradeweb during the last three days of the month averaged 17% more volume and 47% more line items as compared to portfolios traded during the previous days of the month. Portfolio trades near month-end also tend to include more distinct sectors in their make up as compared to portfolio trades happening at other times of the month. Although this is not a direct measure of diversity in bond portfolios, this larger sector range is also indicative of these rebalancing type trades. Portfolio Trading Execution Quality As discussed in earlier blog posts, there are several ways of measuring execution quality for trading in credit markets. One metric we use in our transaction cost analyses is the percentage bid/offer spread captured (%BOS). This is simply the percentage of Tradeweb Ai-Price bid/offer spread that the traded level captured. In H1 2023, we saw improvements in portfolio trade execution quality compared to H1 2022. The median %BOS captured is now very close to mid and has almost returned back to 2021 levels. HY portfolio trade execution quality has also significantly improved since the beginning of the year, despite HY TRACE having fallen around 4% from H1 2022 to H1 2023. We also previously discussed the factors that drive portfolio execution quality at the portfolio level. One interesting trend we wanted to explore further was execution quality at the line level in a portfolio trade and how it varies by size. Intuitively, we would expect higher execution costs on chunkier lines in the portfolio due to a size premium, but also potentially higher costs on those with very small size. This is because a client may be willing to incur slightly higher costs on small trades in order to obtain the certainty of execution on these items. Using H1 2023 Tradeweb portfolio trading data, we looked at how the %BOS captured varied by line size. We can clearly see both in IG and HY that execution quality falls as line size increases, which is expected due to the extra cost associated with trading large sizes. The chart also implies that the optimal size for execution quality is around 50k-500k for IG and 50k-100k in HY, which corresponds with what we tend to see on average for portfolio trades on our platform. The inverted U shape is also indicative of the ‘small trade’ effect where trade costs may be slightly higher for very small line sizes. This implies that clients are willing to accept comparatively worse levels on those bonds since they know they are able to trade them with certainty as part of the broader basket. This effect, however, seems to be much smaller than the higher costs associated with larger line sizes and is still well inside the bid/offer. Looking Forward Even as TRACE volumes declined in Q2 2023 as compared with strong comps in Q1 2023, we’ve seen portfolio trading continue to maintain its significant share of the overall market, and we believe it is here to stay. As the protocol evolves, such as we have seen with the use of Bulk Crossing, we are confident that clients will continue to leverage portfolio trading in innovative ways, and in every market condition. About Tradeweb Markets Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 40 products to clients in the institutional, wholesale and retail markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves approximately 2,500 clients in more than 65 countries. On average, Tradeweb facilitated more than $1.2 trillion in notional value traded per day over the past four quarters. For more information, please go to www.tradeweb.com. Forward-Looking Statements This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading “Risk Factors” in documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future performance and our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release. Contact Details Tradeweb Media Contact Daniel Noonan +1 646-767-4677 Daniel.Noonan@Tradeweb.com Company Website http://www.tradeweb.com

August 17, 2023 10:47 AM Eastern Daylight Time

Image

PathAI Announces Commercial Availability of AISight™ Digital Pathology Image Management System to Power the Next Generation of Pathology Labs

PathAI

PathAI, a global leader in AI-powered pathology, today announced the commercial launch of its AISight TM digital pathology image management system (IMS) for anatomic pathology laboratories. 1 The launch comes at a time when the pathology space is increasingly transitioning to digitally-enabled reads and recognizing the utility of AI and machine learning to enhance quality control, standardize diagnoses, and quantitate biomarkers. AISight is a cloud-based platform that enables efficient, end-to-end digital pathology workflows. AISight provides best-in-class image and case management, ingestion, and viewing while seamlessly enabling access and deployment of AI applications. AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflow adoption. Anatomic pathology laboratories of all sizes and specialties – including health systems, reference laboratories, independent pathology labs, and academic medical centers – may utilize AISight. 1 “We are thrilled to make the AISight Image Management System available to labs globally. We’ve been honing this platform with input from hundreds of pathologists from dozens of institutions, and this launch underpins all of the work PathAI does to support pathologists, biopharma partners, and the academic research community,” said Dr. Andy Beck, M.D. Ph.D., chief executive officer and co-founder of PathAI. “Expanding the feature set to support pathology workflows as an IMS for anatomic pathologist laboratories is a natural progression for PathAI as we strive to meet our mission of improving patient outcomes with AI-powered pathology.” This announcement builds on prior progress as PathAI’s solutions increasingly support digital pathology workflows. In March of this year, PathAI announced the Early Access Program for AISight, and the 12 leading anatomic pathology laboratories that began trialing the platform. Subsequently, PathAI announced the availability of its first 5 algorithm products through the platform including AIM-PD-L1 algorithms across 4 indications, and the AIM-HER2 Breast Cancer algorithm. 2 In addition to AISight for research use, PathAI also has a regulated platform, AISight™ Dx, that has 510(k) clearance for primary digital diagnosis in the US and is CE-marked in the EU. “We have been overwhelmed with the positive feedback from pathologists, lab directors, operators, and administrators who have trialed AISight and we’re excited to make it available at scale,” said Eric Walk, M.D., F.C.A.P., chief medical officer at PathAI. “AISight provides a one-stop shop for digital pathology case management that is flexible for multiple use cases given its interoperability and configurability. We will continue iterating on new and improved features as we listen to our users and release updates as they become available.” To learn more about AISight IMS, register for our upcoming webinar, visit our website, or meet with our team at upcoming conferences including ECP, CAP, and PathVisions. 1 AISight™ is for research use only. Not for clinical use in diagnostic procedures. 2 AIM-PD-L1™ and AIM-HER2™are research use only. Not for clinical use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

August 17, 2023 10:00 AM Eastern Daylight Time

Agora Data Successfully Secures $160 Million in Fourth Private Term Financing

Agora Data, Inc.

Agora Data, Inc., a fintech company transforming automotive financing for U.S. car dealerships by offering abundant, low-cost capital with precision loan performance data and analytics, closed a $160 million private term financing on August 11, 2023. This latest transaction represents the fourth privately placed term financing for Agora. Each of the company’s first three term financings performed better than projected. “To close a term financing transaction in today’s challenging market conditions is proof-positive of the strength of the Agora team and how accurately we manage and predict portfolio performance,” said Steve Burke, CEO, Agora Data. “Fueling Agora’s mission to enable any car dealer to be a finance company, this $160 million private term financing provides additional funding capacity and reiterates our commitment to our customers’ future growth.” The $160 million private term financing marks a significant milestone in Agora Data’s growth trajectory. The company closed the first-ever crowdsourced auto securitization in late 2020, introducing a new way for car dealerships to access capital markets financing by aggregating loan portfolios of varying sizes. The company’s diversified financing strategy has resulted in multiple successful crowdsourced securitizations and private term transactions, all powered by its proprietary artificial intelligence (AI) and machine learning algorithms. With its patent pending modeling that delivers unparalleled accuracy, Agora leverages over $350 billion of loan data for car dealerships to optimize their non-prime portfolios. As a result, more favorable financing terms and highly competitive loan interest rates are available, reshaping the landscape of lending possibilities for dealers and finance companies to finance more non-prime customers, sell more cars, and make more money. Access to abundant capital has been a longstanding challenge for U.S. car dealers who offer or who want to offer financing to non-prime customers. Agora proactively addresses these challenges and presents a transformative fintech approach for dealers to keep their customers and make a gross profit on cars and financing profit on loans. # # # About Agora Data, Inc. Agora Data, Inc. is an automotive industry fintech revolutionizing financing for car dealers and finance companies. Car dealerships can secure affordable capital to build their own non-prime captive finance company, obtain actionable loan performance data to improve their lending portfolios, and use a wide range of solutions to grow their business safely. Powered by patent pending artificial intelligence (AI) and machine learning technology, car dealers can access real-time data analytics and planning resources to help optimize the performance of their portfolios. Agora Data made history by closing the first-ever crowdsourced non-prime auto securitization in 2020 and continually brings groundbreaking financing solutions to an underserved market. For more information, visit www.agoradata.com or contact us at 1-877-592-4672. Contact Details Eric Nemeth nemeth@ericpr.com Company Website https://agoradata.com/

August 17, 2023 09:06 AM Eastern Daylight Time

Quantum Silicon Production Project awarded $5.1m funding under the Defence Trailblazer Program

Silex Systems Limited

August 17, 2023 (AEST): Silex Systems Limited (Silex) (ASX: SLX) (OTCQX: SILXY) is pleased to announce the award of $5.1m in funding from the Defence Trailblazer for Concept to Sovereign Capability Program, a strategic partnership between The University of Adelaide and UNSW Sydney (UNSW), supported by the Australian Government Department of Education through the Trailblazer Universities Program. The funding will support the establishment of a Quantum Silicon Production Plant, which aims to deliver an end-to-end manufacturing facility at the Company’s Lucas Heights technology centre. It is anticipated that the first production module will produce between 5kg to 10kg annually of ZS-Si (in the form of halo-silane), which will then be converted to multiple Q-Si product forms for potential customers in the global silicon-based quantum computing industry. The new project will be undertaken in conjunction with partners, Silicon Quantum Computing Pty Ltd (SQC) and UNSW, and follows on from an earlier project that demonstrated efficient production of gram quantities of ZS-Si, with enrichment of silicon-28 up to ~99.998% purity. Michael Goldsworthy, Silex’s CEO/Managing Director, said: “We are delighted to receive funding under the Federal Government’s Defence Trailblazer Program, which will assist us to transition our Zero-Spin Silicon enrichment technology from the pilot demonstration level to commercial-scale, including the development of product conversion technology to produce two forms of commercial Quantum Silicon products (gas and solid) required by emerging silicon quantum chip fabricators around the world.” “This enables us to capitalise on the results achieved in the recently completed Zero-Spin Silicon Project for our innovative SILEX laser isotope separation technology, and to establish a sovereign capability and secure supply chain for this critical enabling material for the emerging silicon quantum computing industry. Previously, the main supply of enriched silicon came from Russia, but this source has been disrupted by geopolitical events”, he added. Professor Michelle Simmons AO, CEO of SQC, said: “Following the successful collaboration under the CRC-P program, SQC is tremendously excited about the expansion of our partnership with Silex through the Trailblazer Quantum Silicon Production Project. The Trailblazer funding supports Silex’s commercial-scale production of Quantum Silicon, the key enriched silicon material essential to the manufacture of SQC’s atom-scale quantum computers in Australia. The creation of a sovereign supply of this vital material comes at a time when our traditional source of supply has been disrupted. We couldn’t be more motivated to support this Project.” Dr Sanjay Mazumdar, Executive Director, Defence Trailblazer, said: “The Defence Trailblazer looks forward to supporting the commercial deployment of Silex’s Quantum Silicon Production Plant. The intent of the Defence Trailblazer Program is to support the commercialisation of Australian technologies that will have a material benefit to the Defence sector in Australia. Through the Quantum Silicon Production Project, a sovereign end-to-end supply chain for critical quantum materials essential for silicon quantum computing will be created. The advent of quantum computing is expected to have profound impacts on Defence and National Security activities, and this Project is a perfect fit with the intent of the Trailblazer.” Professor Nicholas Fisk, Deputy Vice-Chancellor Research and Enterprise, UNSW Sydney, said: “UNSW Sydney is extremely pleased to support Silex and SQC in the Quantum Silicon Production Project under the Defence Trailblazer Program, in partnership with The University of Adelaide. As a major shareholder in SQC, and as the Administering Organisation for the Australian Research Council Centre of Excellence for Quantum Computation and Communication Technology, we have been impressed with the achievements in the previous CRC-P project for the development of ZS-Si production technology, and are excited to support the next step for commercial-scale production of Quantum Silicon. This Project is of critical importance to Australia’s ability to maintain leadership in an increasingly competitive and strategic endeavour to develop the world’s first scalable quantum computing technology.” Contributing to the ‘ Quantum Materials, Technologies and Computing Theme’ under the Defence Trailblazer Program, quantum computing capability is emerging as a vitally important strategic and national security technology, as evidenced by the global race to establish early mover advantage. The Trailblazer funding will support the commercialisation of Q-Si products for use in defence and civilian markets (domestic and offshore), while cementing areas of critical sovereign capability within Australia. Quantum technologies are expected to have a profound impact on our way of life in the decades to come, with quantum computing to open new frontiers and opportunities for defence and national security. The Q-Si Production Plant will include equipment for conversion of ZS-Si (in the form of halo-silane) into different product forms that are compatible with silicon quantum chip fabrication technologies utilised by manufacturers, namely: Quantum Silane gas – used in chemical vapour deposition (CVD) based processes utilised for quantum chip fabrication Quantum Silicon solid – used in atomic and molecular beam epitaxy (ABE / MBE) based processes utilised for quantum chip fabrication. A key benefit of the SILEX laser isotope separation technology is its modular nature, allowing the possibility for the production plant to be scaled up with additional modules, based on market demand and other factors. The 3.5-year Project has a total budget of ~$16m, of which $5.1m in funding will be provided by the Defence Trailblazer. Silex is currently resolving other avenues of financial support for the Project. Authorised for release by the Silex Board of Directors. Further information on the Company’s activities can be found on the Silex website: www.silex.com.au or by contacting investor.relations@silex.com.au. Forward Looking Statements and Risk Factors: About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) Silex Systems Limited ABN 69 003 372 067 ( Silex or the Company ) is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company’s technology facility in Sydney, Australia. The SILEX technology has been under development for uranium enrichment jointly with US-based exclusive licensee Global Laser Enrichment LLC (GLE) for a number of years. Success of the SILEX uranium enrichment technology development program and the proposed Paducah commercial project remain subject to a number of factors including the satisfactory completion of the engineering scale-up program and nuclear fuel market conditions and therefore remains subject to associated risks. Silex is also at various stages of development of additional commercial applications of the SILEX technology, including the production of ‘Zero-Spin Silicon’ for the emerging technology of silicon-based quantum computing. The ‘Quantum Silicon’ project remains dependent on the outcomes of the project and the viability of silicon quantum computing and is therefore subject to various risks. Silex is also conducting research activities in its Medical Isotope Separation Technology (MIST) Project, which is early-stage and subject to numerous risks. The commercial future of the SILEX technology in application to uranium, silicon, medical and other isotopes is therefore uncertain and any plans for commercial deployment are speculative. Additionally, Silex has an interest in a unique semiconductor technology known as ‘cREO ® ’ through its 100% ownership of subsidiary Translucent Inc. The cREO ® technology developed by Translucent has been acquired by IQE Plc based in the UK. IQE has paused the development of the cREO ® technology until a commercial opportunity arises. The future of IQE’s development program for cREO ® is very uncertain and remains subject to various technology and market risks. Forward Looking Statements The commercial potential of these technologies is currently unknown. Accordingly, no guarantees as to the future performance of these technologies can be made. The nature of the statements in this Announcement regarding the future of the SILEX technology as applied to uranium enrichment, Zero-Spin Silicon production, medical and other isotope separation projects, the cREO ® technology and any associated commercial prospects are forward-looking and are subject to a number of variables, including but not limited to, unknown risks, contingencies and assumptions which may be beyond the control of Silex, its directors and management. You should not place reliance on any forward-looking statements as actual results could be materially different from those expressed or implied by such forward-looking statements as a result of various risk factors. Further, the forward-looking statements contained in this Announcement involve subjective judgement and analysis and are subject to change due to management’s analysis of Silex’s business, changes in industry trends, government policies and any new or unforeseen circumstances. The Company’s management believes that there are reasonable grounds to make such statements as at the date of this Announcement Silex does not intend, and is not obligated, to update the forward-looking statements except to the extent required by law or the ASX Listing Rules. Risk Factors Risk factors that could affect future results and commercial prospects of Silex include, but are not limited to: ongoing economic and social uncertainty, including in relation to the impacts of the COVID-19 pandemic; geopolitical risks, in particular relating to Russia’s invasion of Ukraine and tensions between China and Taiwan which may impact global supply chains, among other risks; uncertainties related to the effects of climate change and mitigation efforts; the results of the GLE/SILEX uranium enrichment pilot demonstration program; the market demand for natural uranium and enriched uranium; the outcome of the project for the production of ‘Zero-Spin Silicon’ for the emerging technology of silicon-based quantum computing; the outcome of the MIST Project; the potential development of, or competition from alternative technologies; the potential for third party claims against the Company’s ownership of Intellectual Property; the potential impact of prevailing laws or government regulations or policies in the USA, Australia or elsewhere; whether IQE’s commercialisation program for cREO ® is resumed, the results from the program and the market opportunities for cREO ® products; actions taken by the Company’s commercialisation partners and other stakeholders that could adversely affect the technology development programs and commercialisation strategies; and the outcomes of various strategies and projects undertaken by the Company. Contact Details Silex Systems Limited Michael Goldsworthy | Julie Russell +61 2 9704 8888 investor.relations@silex.com.au Company Website https://www.silex.com.au/

August 17, 2023 09:00 AM Eastern Daylight Time

Wishpond Reports Continued Revenue and Adjusted EBITDA Growth in Q2-2023

Wishpond Technologies Ltd.

Wishpond Technologies Ltd. (TSXV: WISH, OTCQX: WPNDF) (the “ Company ” or “ Wishpond ”), a provider of marketing-focused online business solutions, announces it has filed its interim consolidated financial statements (the “ Interim Financial Statements'' ) and management’s discussion and analysis (the “ MD&A ”) for Q2-2023, representing the three and six months ended June 30, 2023. Copies of the Interim Financial Statements and MD&A are available on the Company’s profile on SEDAR at www.sedar.com. Ali Tajskandar, Wishpond’s Founder and CEO commented, “ We are very pleased with our second quarter results in which Wishpond achieved positive Adjusted EBITDA for the fourth quarter in a row, demonstrating our commitment to profitable growth. During the first six months of 2023 we generated $0.4 million of positive Adjusted EBITDA compared to an Adjusted EBITDA loss of $0.6 million in the first six months of last year; an outstanding improvement of over $1 million, which we are extremely proud of achieving. Wishpond’s cost optimization efforts over the past year have contributed to the Company’s positive Adjusted EBITDA profile. Based on the Company’s performance and growth momentum in the first half of the year, we expect to deliver strong results for the remainder of 2023. We maintain a positive outlook for the second half of 2023, with continued sales growth and improving cash flows.” Ali Tajskandar further adds, “During the second quarter we also completed the acquisition of Essential Studio Manager (ESM), which is the sixth acquisition in the Company’s history. ESM further expands the breadth of our product offering into invoicing, CRM and business management functionality. In addition, we are actively working on developing additional AI-powered marketing tools which we intend to launch in the coming quarters. Finally, our new Propel IQ platform is gaining traction in the market and early signs are showing higher margins and increased customer retention. We are now accelerating the hiring of new sales resources to drive additional growth in the second half of the year.” Second Quarter 2023 Financial Highlights: Wishpond achieved quarterly revenue of $5,639,417 during Q2-2023, compared to $5,007,343 generated in the same period of 2022 (Q2-2022), an increase of 13%. Revenue growth was primarily driven by organic growth resulting from stronger product demand, an increase in sales and marketing activities, and new product introductions. Wishpond achieved Gross Profit of $3,680,391 in Q2-2023 (Q2-2022: $3,360,715), representing a 10% increase from Q2-2022, driven by an increase in overall revenue. Wishpond achieved a Gross Margin percentage of 65% during Q2-2023 (Q2-2022: 67%). During Q2-2023, Wishpond achieved positive Adjusted EBITDA (1) of $215,926 (Q2-2022: negative $192,196), an increase of 212%. As at June 30, 2023, Wishpond had $1,098,285 in cash and no debt (December 31, 2022: cash of $2,692,644 and no debt). The reduction in cash balances was caused in part by earnout payments for businesses acquired in 2022, investment in the business and changes in working capital. Second Quarter 2023 Business Highlights: On May 3, 2023, the Company announced that it completed the acquisition of certain assets of Essential Studio Manager LLC (“ESM”). ESM is a provider of business management software, including invoicing and customer relationship management solutions for small businesses in the services industry. ESM is expected to be integrated with Wishpond’s Propel IQ platform this year. Wishpond customers using Propel IQ’s sales and marketing platform will then be able to provide contract signing, invoicing and access other CRM functionality from one single platform. On June 27, 2023, the Company announced that its Notice of Intention to make a Normal Course Issuer Bid (“NCIB”) was accepted by the Exchange. Under the NCIB, the Company may, during the 12-month period commencing June 30, 2023 and ending June 29, 2024, purchase up to 2,688,431 Shares in total, being 5% of the total number of 53,768,620 Shares outstanding as at June 12, 2023. During the three and six months ended June 30, 2023, the Company purchased 32,000 common shares under the NCIB, for aggregate consideration of $18,528. Events Subsequent to June 30, 2023: On July 27, 2023, the Company announced the launch of a new partnership program introducing a transformative approach to collaboration for affiliates, marketing agencies, and other technology companies to collaborate closely with Wishpond’s marketing platform. On August 16, 2023, the Company announced the upcoming launch of SalesCloser AI, an AI-powered sales rep that can deliver personalized, round-the-clock sales calls and product demos without the need for human intervention. The AI-powered platform is poised to transform industries across the board, particularly benefiting virtual sales professionals, SaaS companies, consultants, and various B2B enterprises that rely on online sales interactions. Outlook: Wishpond expects to achieve record revenue and cash flows in 2023, driven by organic growth from increasing sales of the Company’s new Propel IQ bundled product, in addition to ramping up the size of its sales team and launching new AI-powered products. The Company continues to have an active pipeline of sales opportunities and robust demand for its products. Management is pleased to re-iterate the Company’s key goals for 2023: Increase Monthly Recurring Revenue through both organic and inorganic means. Scale the size of the sales team to help achieve the Company’s organic growth profile. Remain Adjusted EBITDA positive by balancing growth with increased positive cash flow from operations. Invest in Research and Development so that the Company can continue to launch new AI powered products and services to increase long-term value for its clients. Leverage the Propel IQ platform to further accelerate the Company’s growth, improve margins, and increase customer retention and long-term customer value. Wishpond has demonstrated a disciplined capital allocation strategy, having successfully completed and integrated six acquisitions since the Company’s public listing in December of 2020. Given management’s successful acquisition track record, the Company may choose to accelerate its growth in the form of future acquisitions. Management may also choose to reinvest cash flows generated by the Company to accelerate organic growth or in the form of share repurchases. David Pais, Wishpond’s Chief Financial Officer commented, “ I am pleased to report that the Company has not felt any material negative impacts due to increasing interest rates, rising inflation or other macroeconomic effects. We have a clean balance sheet and an undrawn line of credit of $6 million, and our cost reduction strategies will allow us to fund the Company’s growth through cash from operations. We look forward to reporting higher revenue growth and profitability for the rest of the year. ” Webinar Conference Call Details: As previously announced, Wishpond will be hosting a webinar conference call to discuss its Q2-2023 financial results today at 10:00 AM (PT) / 1:00 PM (ET). To register for the webinar, please visit the following URL: https://bit.ly/Results_Q2_2023 Date: August 17, 2023 Time: 10:00 AM PT (1:00 PM ET) Dial-in: +1 778 907 2071 (Vancouver local) +1 647 374 4685 (Toronto local) Meeting ID #: 835 0694 7063 Please connect 5 minutes prior to the conference call to ensure time for any software download that may be required. Selected Financial Highlights: The tables below set out selected financial information relating to Wishpond and should be read in conjunction with Wishpond’s Interim Financial Statements and MD&A. Reconciliation to Adjusted EBITDA Footnotes: EBITDA and Adjusted EBITDA a re not financial measures recognized by International Financial Reporting Standards (“ IFRS ”), do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other entities. See “ Cautionary Statements – Non-GAAP Financial Measures ". On Behalf of the Board of Wishpond “ Ali Tajskandar ” Chairman and Chief Executive Officer About Wishpond Technologies Ltd. Based out of Vancouver, British Columbia, Wishpond is a provider of marketing-focused online business solutions. Wishpond is a leading provider of digital marketing solutions that empower entrepreneurs to achieve success online. The Company’s Propel IQ platform offers an "all-in-one" marketing suite that provides companies with marketing, promotion, lead generation, ad management, referral marketing, sales conversion and outbound sales automation capabilities on one integrated platform. Wishpond replaces disparate marketing solutions with an easy-to-use product, for a fraction of the cost. Wishpond serves over 4,000 customers who are primarily small and medium-sized businesses (SMBs) in a wide variety of industries. The Company has developed cutting-edge marketing technology solutions including an artificial intelligence (AI) powered website builder and continues to add new features and applications. The Company employs a Software-as-a-Service (SaaS) business model where most of the Company's revenue is subscription-based recurring revenue which provides excellent revenue predictability and cash flow visibility. Wishpond is listed on the TSX Venture Exchange under the ticker "WISH", and on the OTCQX Best Market under the ticker "WPNDF". For further information, visit: www.wishpond.com. Cautionary Statements, Summary Information Information presented in this press release may be only a summary of all available information and does not purport to be a full representation of all figures, notes and discussions provided for in the Interim Financial Statements and MD&A. Readers are cautioned to read the entirety of the Interim Financial Statements and MD&A, and to not rely only on the information presented in this press release. In the event of conflict between the provisions of this press release on the one hand, and the Interim Financial Statements and MD&A on the other hand, the information in the Interim Financial Statements and MD&A shall govern. Non-GAAP Financial Measures In this press release, Wishpond has used the following terms (“ Non-GAAP Financial Measures ”) that are not defined by IFRS, but are used by management to evaluate the performance of Wishpond and its business: adjusted earnings before interest, taxes, depreciation and amortization (“ Adjusted EBITDA ”), monthly recurring revenue. These measures may also be used by investors, financial institutions and credit rating agencies to assess Wishpond’s performance and ability to service debt. Non-GAAP Financial Measures do not have standardized meanings prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Securities regulations require that Non-GAAP Financial Measures are clearly defined, qualified and reconciled to their most comparable IFRS financial measures. Except as otherwise indicated, these Non-GAAP Financial Measures are calculated and disclosed on a consistent basis from period to period. Specific items may only be relevant in certain periods. See the disclosure under the heading “ Additional GAAP and Non-GAAP Measures ” in Wishpond’s MD&A for a discussion of Non-GAAP Financial Measures and certain reconciliations to GAAP financial measures. The intent of Non-GAAP Financial Measures is to provide additional useful information to investors and analysts, and the measures do not have any standardized meaning under IFRS. The measures should not, therefore, be considered in isolation or used as a substitute for measures of performance prepared in accordance with IFRS. Other issuers may calculate Non-GAAP Financial Measures differently. Non-GAAP Financial Measures are identified and defined as follows: Adjusted EBITDA: Adjusted EBITDA should not be construed as an alternative to net earnings, cash flow from operating activities or other measures of financial results determined in accordance with GAAP as an indicator of the Company’s performance. The Company defines " Adjusted EBITDA " as Loss before income taxes less interest, depreciation and amortization, remeasurement of contingent consideration liability, filing fees, credit facility setup fees, earn-out remuneration, foreign currency losses (gains), acquisition related expenses, net other expenditures (income), reverse takeover listing expense, and stock-based compensation. The Company believes that Adjusted EBITDA is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements, service future interest and principal debt repayments and fund future growth initiatives. Monthly recurring revenue: The Company uses monthly recurring revenue, or MRR, as a directional indicator of subscription revenue going forward assuming customers maintain their subscription plan the following month. MRR is the total of all monthly subscription plan fees paid by customers in effect on the last day of that period. If customers pay for more than one month upfront, the amount is divided by the number of months in the subscription period. Discounts are deducted prior to the calculation and one-time payments and metered based charges are excluded. Forward-Looking Statements Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, " forward-looking statements "). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about, among other things, all information contained under the heading “Outlook” herein, references to expected results from future operations, references to the growth of the Company’s product portfolio, including whether additional AI powered products or features may be developed in the future, and the functionality and timing of such products, financial results or operational activities that may be undertaken by the Company, the results of the Company’s cost-savings, research and development and other initiatives, any future acquisitions, share purchases or other activities done to grow the Company both organically or inorganically, expectations, beliefs, plans, future operations, origination of additional targets in which the Company may hold an interest and acquisition opportunities for the Company, the impact of broader economic factors including inflation and other general economic risks on the Company, business and acquisition strategies, opportunities, objectives, prospects, assumptions, including those related to trends and prospects, and future events and performance. Sentences and phrases containing or modified by words such as “expect”, "anticipate", "plan", "continue", "estimate", "intend", "expect", "may", "will", "project", "predict", "potential", "targets", "projects", "is designed to", "strategy", "should", "believe", "contemplate" and similar expressions, and the negative of such expressions, are not historical facts and are intended to identify forward-looking statements. Readers are cautioned to not place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and are based on, among other things, the expectations and analysis of current market trends and opportunities of management of the Company, such forward-looking statements has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to, economic uncertainty and instability as a result of the ongoing inflation and supply chain issues, higher interest rate climate, tightening of credit availability and recessionary risks, pandemic related risks, wars, instability in global commodity and securities markets, shifts in consumer and institutional spending and marketing strategies, risks related to data breaches and privacy, the changing global market and competition for the products and services supplied by the Company, and the additional risk factors discussed in the continuous disclosure materials of the Company which are available under the Company's profile on SEDAR at www.sedar.com. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Details Investor Relations, Wishpond Technologies Ltd. Pardeep S. Sangha +1 604-572-6392 investor@wishpond.com

August 17, 2023 07:00 AM Eastern Daylight Time

G MEDICAL INNOVATIONS WILL PROVIDE SERVICES TO VETERANS AND MILITARY PERSONNEL BY PARTNERING WITH RESILIENT SUPPORT SERVICES

G-Medical Innovations Holdings Ltd

Rehovot, Israel, August 17 th, 2023 – G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations”), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with Resilient Support Services Inc. (“RSS”) to expand the health care and remote patient monitoring capabilities to U.S. veterans and military personnel. RSS is a Service-Disabled Veteran-Owned Business that partners with U.S. federal agencies and private sector businesses that are concerned with improving the medical care of veterans and the military community. G Medical Innovations’ innovative technology will help federal agencies and military personnel to better monitor and diagnose new onset cardiovascular symptoms as part of a growing need in virtual care. This will allow full access to near real-time patient information which will also be analyzed by certified cardiac monitoring technicians through G Medical Innovations’ own independent diagnostic testing facility. Available to both adult and pediatric patients, this cloud-based monitoring system includes a small, water-resistant monitor that patients will receive by mail or in person. Patient’s symptoms can then be monitored in near real-time from the comfort of their home. Those who experience unusual arrhythmias or other monitored symptoms receive immediate communication from providers, enabling greater access to care and, in some cases, earlier diagnoses of serious medical conditions. The use of the G Medical Prizma device will allow for state-of-the-art remote patient monitoring (RPM) in the comfort of their home. This care experience platform ensures that patients remain connected with their care teams through next-generation devices to improve clinical decision-making. The patients will be able to download the G Medical app and receive a digital health kit to measure biometric data in one single device. “We are excited to have G Medical Innovations provide their powerful technology and 31 test kits to those serving our country in veteran affairs and all military branches here and abroad. Innovations like this will help protect and improve the care of our veterans and military serving soldiers, now and into the future,” explained Robert Domenici, Lieutenant Colonel (USA Ret.) President and CEO, RSS Inc. “We are delighted to say that we could not find a better partner to serve veterans affairs and all military branches than RSS Inc. G Medical is committed to providing the highest level of care and service to our veterans and military personnel,” said Dr. Yacov Geva, Chief Executive Officer and Founder of G Medical Innovations. About G Medical Innovations G Medical Innovations is a healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing multi-channel patient-worn biosensors with algorithms, to generate real time analysis and transmission that captures electrocardiography data continuously, including QT syndrome prolongation detection. In addition, the Company is developing its wireless vital signs monitoring system, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of independent diagnostic testing facility monitoring services and private monitoring services. For more information about G Medical innovations, visit https://gmedinnovations.com/. About Resilient Support Services Resilient Support Services Inc. (RSS Inc.) is an experienced multi-faceted certified service-disabled veteran-owned business providing strategic advisory services to companies looking to navigate, identify and capitalize on the vast procurement complexities and opportunities within the federal, state, local government and the commercial sectors. The company has a wide-array of health/safety, defense, industrial supply and construction products and service offerings available to its government and commercial clients within the US and abroad. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical Innovations is using forward-looking statements when it discusses the services and products to be provided by the Company to Resilient Support Services Inc and the potential benefits of G Medical Innovations’ technology and specifically the G Medical Prizma device to end users. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical Innovations could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s Innovations Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on May 16, 2023, and our other filings with the SEC, which are available on the SEC’s website, www.sec.gov. Except as otherwise required by law, G Medical Innovations undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Investor Relations Contact G Medical Innovations service@gmedinnovations.com G Medical Innovations Holdings Ltd. is a health care company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both health care providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing multi-channel patient-worn biosensors with algorithms, to generate real time analysis and transmission that captures electrocardiography data continuously, including QT syndrome prolongation detection. In addition, the Company is developing its wireless vital signs monitoring system, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of independent diagnostic testing facility monitoring services and private monitoring services. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical Innovations is using forward-looking statements when it discusses: revenue growth and profitability in future periods; the launch of the Company’s CLIA lab in Austin, TX, the Company’s online store for its Prizma Monitoring Devices on Amazon Marketplace and the Company’s HTKs business and online stores; potential announcements with large homecare service companies and large distributors for devices and At Home Test Kits; and the Company’s plans to expand its line of monitoring products and services offered to patients, hospitals and clinics. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical Innovations could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,, including those discussed under the heading “Risk Factors” in G Medical’s Innovations Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on May 16, 2023, and our other filings with the SEC, which are available on the SEC’s website, www.sec.gov. Except as otherwise required by law, G Medical Innovations undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details G Medical Innovations G Medical Innovations +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com

August 17, 2023 06:00 AM Eastern Daylight Time